#Apalutamide
LightNews LightNews
therapies.bsky.social
Pharmacovigilance
Lichenoid drug eruption and apalutamide: Analyses from pharmacovigilance databases and disproportionality analysis
#Apalutamide #LichenoidDrugEruption #Pharmacovigilance
www.em-consulte.com/article/1717...
Lichenoid drug eruption and apalutamide: Analyses from pharmacovigilance databases and disproportionality analysis
Lichenoid drug eruption and apalutamide: Analyses from pharmacovigilance databases and disproportionality analysis
www.em-consulte.com
February 6, 2025 at 7:54 AM
keeperoftheember.bsky.social
DO PATIENTS HAVE ACCESS TO APALUTAMIDE?
DEGARELIX + APALUTAMIDE IS BEING TESTED, AND I WOULD WANT THEM ALL IN: AT 12 DAYS THERE IS AN APPRECIABLE IMPROVEMENT IN MY OVERALL WELLBEING. NO VOMITTING SINCE I BEGAN AND REST COMES MUCH EASIER - GOOD SIGNS. AS AN ADJUNCT I WILL SEEK MORE OF THIS CHEMICAL.
December 15, 2024 at 8:28 AM
oncoalert.bsky.social
Post hoc analysis of TITAN examined the association between achieving ultralow prostate-specific antigen (PSA) levels (≤0.2 ng/mL) and clinical outcomes in patients with metastatic castration-sensitive #ProstateCancer (mCSPC) treated with apalutamide.
https://buff.ly/3CJA5bO
November 19, 2024 at 2:20 PM
apccc.bsky.social
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive #ProstateCancer (TITAN)

acsjournals.onlinelibrary.wiley.com/doi/full/10....

findings suggest that baseline bone metastasis count may help identify optimal candidates for apalutamide tx in mCSPC.
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration‐sensitive prostate cancer
In this post-hoc analysis of a phase 3 randomized controlled trial comparing apalutamide versus placebo in metastatic castration-sensitive prostate cancer, patients with two or less bone metastases h...
acsjournals.onlinelibrary.wiley.com
March 21, 2025 at 2:18 PM
nejm.org
In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: https://nej.md/3RuNe00

#ASCO26
A survival analysis graph from a study published in the New England Journal of Medicine shows the percentage of patients over time in months since randomization. The graph compares "ADT plus apalutamide" to "ADT plus placebo." Data includes hazard ratios and confidence intervals. The American Society of Clinical Oncology Meeting is mentioned at the top.
May 31, 2026 at 12:07 PM
gmj-georgia.bsky.social
🔬 PROTEUS trial in Nature Medicine (June 2026) shows perioperative apalutamide + androgen-deprivation therapy offer new hope for high-risk prostate cancer patients before surgery. This&he…

https://news.gmj.ge/briefs/announcement-proteus-trial-shows-promise-for-perioperative-prostate-cancer-therapy/
Announcement: PROTEUS Trial Shows Promise for Perioperative Prostate Cancer Therapy
🔬 PROTEUS trial in Nature Medicine (June 2026) shows perioperative apalutamide + androgen-deprivation therapy offer new hope for high-risk prostate cancer patients before surgery. This&he…
news.gmj.ge
September 25, 2026 at 3:27 PM
bild.bsky.social
Apalutamide + Hormon tedavisi (ADT) kombinasyonu, sadece hormon tedavisi alanlara kıyasla metastaz veya ölüm riskini %20 oranında azalttı. 5 yıllık "metastazsız sağkalım oranı apalutamide grubunda %78,2 olarak gerçekleşti ve bu diğer grupta %73,5.
​
May 31, 2026 at 4:59 PM
onclive.bsky.social
WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here 📽️: www.onclive.com/view/dr-bile...
#oncology #pcsm #mcspc
Dr Bilen on Real-World OS Benefit With Apalutamide vs Darolutamide in mCSPC | OncLive
Mehmet Bilen, MD, discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
www.onclive.com
February 23, 2026 at 1:46 PM
ascocancer.bsky.social
Phase 3 PROTEUS study, presented at #ASCO26, found a potential new targeted treatment (apalutamide+ADT) option for ppl w local High⬆️ risk #ProstateCancer. @williamohmd.bsky.social weighs in.

Read the abstract: https://bit.ly/3Rz7vl2
May 31, 2026 at 6:11 PM
linglingtian.bsky.social
📊 New real-world evidence:How do apalutamide and enzalutamide compare for PSA response in metastatic castration-sensitive prostate cancer?
This study provides important comparative insights to inform treatment decisions.
🔗 Read now: buff.ly/CsFU3XV
#ProstateCancer #Oncology #RealWorldEvidence #mCSPC
June 6, 2026 at 7:02 AM
crisbergerot.bsky.social
Investigating the association of statin use with overall survival and cardiac adverse events in patients w advanced prostate cancer treated with apalutamide. 📊 A pooled analysis of TITAN and SPARTAN @ascocancer.bsky.social #GU25
February 13, 2025 at 8:05 PM
bild.bsky.social
Hastalar, ameliyattan 6 ay önce apalutamide + hormon tedavisi almaya başlıyor. Ardından prostatın tamamen alınması yani radikal prostatektomi ameliyatı yapılıyor.
​Ameliyattan sonra 6 ay daha aynı tedaviye devam ediliyor.
​
May 31, 2026 at 5:01 PM
bild.bsky.social
Yüksek riskli, lokalize veya bölgesel ileri evre prostat kanseri olan hastalarda, cerrahi işleme ek olarak uygulanan apalutamide tedavisi, kanserin yayılma yani metastaz ve ölüm riskini önemli ölçüde azalttı.
​
May 31, 2026 at 4:58 PM
journal-cer.bsky.social
📢New article alert

New Short Report on "Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide".

🔗Read here: becarispublishing.com/doi/10.57264...

#OpenAccess #JCER #ProstateCancer #RWE
Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide
Aim: There is limited real-world evidence about prostate-specific antigen (PSA) response to androgen receptor pathway inhibitor treatment in Black patients with metastatic castration-sensitive prostat...
becarispublishing.com
January 23, 2026 at 4:47 PM
crisbergerot.bsky.social
Examining the real-world use and outcomes of darolutamide (DARO), enzalutamide (ENZA), and apalutamide (APA) in nmCRPC through a race subgroup analysis. 🧬 Insights on treatment disparities and outcomes in advanced prostate cancer @ascocancer.bsky.social #GU25
February 13, 2025 at 8:02 PM
nejm.org
Phase 3 PROTEUS trial: Neoadjuvant systemic therapy and surgical resection are standard for many cancers, but this approach has not shown benefit in prostate cancer. Research findings on perioperative treatment with apalutamide are summarized in a new Quick Take video. https://nej.md/3TT00q8
A silhouette of a patient with high-risk localized or locally advanced prostate cancer is on the left, with a red target symbol on the lower abdomen. On the right is an illustration of a prostate gland. Below are three circular icons: two with pills and one with a scalpel, connected by arrows, indicating perioperative treatment with apalutamide, an oral nonsteroidal androgen-receptor inhibitor, in addition to androgen-deprivation therapy (ADT).
August 8, 2026 at 1:00 PM
onclive.bsky.social
WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here ➡️: www.onclive.com/view/dr-bile...
#oncology #medtwitter #prostatecancer #pcsm #mcspc
Dr Bilen on a Real-World Analysis of Apalutamide vs Darolutamide in mCSPC | OncLive
Mehmet Bilen, MD, discusses the rationale for a real-world analysis of apalutamide vs darolutamide in mCSPC.
www.onclive.com
February 20, 2026 at 10:35 PM
onclive.bsky.social
Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC @emoryuniversity.bsky.social @winshipcancer.emory.edu #pcsm #oncology
www.onclive.com/view/real-wo...
Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC | OncLive
Mehmet Bilen, MD, discusses a retrospective analysis of patients receiving apalutamide vs darolutamide for metastatic castration-sensitive prostate cancer.
www.onclive.com
February 10, 2026 at 10:56 PM
tiansterzhangmd.bsky.social
#MaryEllenTaplin @DanaFarber_GU with first plenary of the day @asco #ASCO26 — phase 3 of #PROTEUS — >2100 patients w high risk #prostatecancer, adt and apalutamide improved path CR and also a highly powered statistically significant MFS benefit.
@oncoalert @urotoday @PCF_Science
May 31, 2026 at 6:42 PM
onclive.bsky.social
WATCH: Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC #AUA26 #pcsm #oncology
www.onclive.com/view/dr-scho...
Dr Schoen on a Real-World Study of Enzalutamide vs Apalutamide in mCSPC | OncLive
Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC.
www.onclive.com
May 18, 2026 at 8:28 PM
icrdduiit.bsky.social
🚨 Now recruiting at the DDU: ASpiRE, a Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC), testing SX-682 + Apalutamide. Help shape the future of prostate cancer care.

📍Royal Marsden, Sutton

🔗ClinicalTrials.gov (NCT07002320)

#ProstateCancer #ASpiRETrial #DDU #ICR
June 23, 2025 at 11:31 AM
onco404.bsky.social
✅ High-Risk MMAI Patients: Showed significant improvement with apalutamide vs. placebo (MFS HR 0.19, PFS2 HR 0.47, OS HR 0.6).
✅ Non-High-Risk MMAI Patients: Showed no significant difference in outcomes with apalutamide vs. placebo.

#Onco404 #Cancer #Kanser #OncSky #AI
May 1, 2025 at 6:19 PM
danafarber.bsky.social
In today’s plenary session, Mary-Ellen Taplin, MD, shares positive results from the PROTEUS trial showing patients treated with the apalutamide plus hormone therapy regimen were ten times more likely to have little to no cancer present at surgery. #ASCO26
May 31, 2026 at 6:20 PM
onco404.bsky.social
📊 Key Findings
✅ Prognostic: Higher MMAI scores correlated with shorter Metastasis-Free Survival (MFS, HR 1.72), PFS2 (HR 1.57), and Overall Survival (OS, HR 1.41).
✅ Predictive: MMAI identified patients deriving the most benefit from adding apalutamide to ADT.

#Onco404 #Cancer #Kanser #MedSky #AI
May 1, 2025 at 6:19 PM
nejm.org
In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full PROTEUS trial results and Research Summary: https://nej.md/3RuNe00
August 10, 2026 at 7:00 PM